IL303045A - Antibodies that bind gamma-delta t cell receptors - Google Patents

Antibodies that bind gamma-delta t cell receptors

Info

Publication number
IL303045A
IL303045A IL303045A IL30304523A IL303045A IL 303045 A IL303045 A IL 303045A IL 303045 A IL303045 A IL 303045A IL 30304523 A IL30304523 A IL 30304523A IL 303045 A IL303045 A IL 303045A
Authority
IL
Israel
Prior art keywords
antibody
seq
antigen
set forth
binding region
Prior art date
Application number
IL303045A
Other languages
English (en)
Hebrew (he)
Inventor
Paul Willem Henri Ida Parren
Robertus Cornelis Roovers
Der Vliet Johannes Jelle Van
Hulsik David Lutje
Peter Alexander Gerardus Maria Machielsen
Westerhoven Michiel Van
Lisa Anna King
Felix-Lennart Fennemann
Original Assignee
Lava Therapeutics N V
Paul Willem Henri Ida Parren
Robertus Cornelis Roovers
Der Vliet Johannes Jelle Van
Hulsik David Lutje
Peter Alexander Gerardus Maria Machielsen
Westerhoven Michiel Van
Lisa Anna King
Fennemann Felix Lennart
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lava Therapeutics N V, Paul Willem Henri Ida Parren, Robertus Cornelis Roovers, Der Vliet Johannes Jelle Van, Hulsik David Lutje, Peter Alexander Gerardus Maria Machielsen, Westerhoven Michiel Van, Lisa Anna King, Fennemann Felix Lennart filed Critical Lava Therapeutics N V
Publication of IL303045A publication Critical patent/IL303045A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL303045A 2020-12-10 2021-12-09 Antibodies that bind gamma-delta t cell receptors IL303045A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20213166 2020-12-10
PCT/EP2021/085079 WO2022122973A1 (en) 2020-12-10 2021-12-09 Antibodies that bind gamma-delta t cell receptors

Publications (1)

Publication Number Publication Date
IL303045A true IL303045A (en) 2023-07-01

Family

ID=73793117

Family Applications (1)

Application Number Title Priority Date Filing Date
IL303045A IL303045A (en) 2020-12-10 2021-12-09 Antibodies that bind gamma-delta t cell receptors

Country Status (10)

Country Link
US (1) US20230303694A1 (https=)
EP (1) EP4259660A1 (https=)
JP (1) JP2024501403A (https=)
KR (1) KR20230157933A (https=)
CN (1) CN116888153A (https=)
AU (1) AU2021395439A1 (https=)
CA (1) CA3200826A1 (https=)
IL (1) IL303045A (https=)
MX (1) MX2023006832A (https=)
WO (1) WO2022122973A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116323667A (zh) 2020-07-08 2023-06-23 拉法医疗股份有限公司 结合PSMA和γ-δT细胞受体的抗体
EP4292609A1 (en) 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Compositions comprising antibodies that bind gamma-delta t cell receptors
EP4292610A1 (en) * 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Variant antibodies that bind gamma-delta t cell receptors
WO2024200573A1 (en) 2023-03-27 2024-10-03 LAVA Therapeutics N.V. Nectin-4 binding agents and methods of use
WO2025012118A2 (en) 2023-07-07 2025-01-16 LAVA Therapeutics N.V. 5t4 binding agents and methods of use
TW202519261A (zh) 2023-07-27 2025-05-16 荷蘭商拉法醫療公司 用於治療癌症之結合γ-δ T細胞受體之抗體
WO2025128615A1 (en) * 2023-12-12 2025-06-19 Seagen Inc. Multispecific egfr antibodies and use in the treatment of cancer
TW202535922A (zh) * 2023-12-18 2025-09-16 美商思進公司 治療ｅｇｆｒ突變癌症之方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
WO2010111625A1 (en) 2009-03-27 2010-09-30 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
PL2606064T3 (pl) 2010-08-16 2015-07-31 Novimmune Sa Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał
SI2838917T1 (sl) 2012-04-20 2019-11-29 Merus Nv Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul
DK2924052T3 (da) 2012-11-21 2019-09-30 Pharmabcine Inc Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme
EP3129404B1 (en) * 2014-04-10 2026-01-28 LAVA Therapeutics N.V. Immunoglobulins binding human vgamma9vdelta2 t cell receptors
WO2020060406A1 (en) 2018-09-19 2020-03-26 Lava Therapeutics B.V. Novel bispecific antibodies for use in the treatment of hematological malignancies
CN113993893A (zh) * 2019-02-01 2022-01-28 拉法医疗有限公司 新cd40结合抗体
EP3792283A1 (en) 2019-09-16 2021-03-17 Lava Therapeutics B.V. Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies

Also Published As

Publication number Publication date
CA3200826A1 (en) 2022-06-16
EP4259660A1 (en) 2023-10-18
CN116888153A (zh) 2023-10-13
KR20230157933A (ko) 2023-11-17
AU2021395439A9 (en) 2024-09-12
US20230303694A1 (en) 2023-09-28
MX2023006832A (es) 2023-08-22
AU2021395439A1 (en) 2023-06-22
WO2022122973A1 (en) 2022-06-16
JP2024501403A (ja) 2024-01-12

Similar Documents

Publication Publication Date Title
US20230303694A1 (en) Antibodies that bind gamma-delta t cell receptors
AU2022223152B2 (en) Anti-gprc5d×bcma×cd3 trispecific antibody and use thereof
US20250230240A1 (en) Variant antibodies that bind gamma-delta t cell receptors
IL299748A (en) Antibodies that bind PSMA and T gamma delta receptors
US20240392020A1 (en) Antigen-binding molecule
US20240141071A1 (en) Antibodies that bind cd123 and gamma-delta t cell receptors
EP4495139A1 (en) Antigen-binding molecule specifically binding to gprc5d and cd3 and medical use thereof
EP4292609A1 (en) Compositions comprising antibodies that bind gamma-delta t cell receptors
EP4438624A1 (en) Antibodies that bind nectin-4 and gamma-delta t cell receptors
US20260092124A1 (en) Anti-cd40 antibody constructs with high intrinsic agonism
HK40118288A (zh) 包含结合γ-δ T细胞受体的抗体的组合物
TW202528360A (zh) 藉由重組反應製備異源多聚體的方法
IL305346A (en) Antibodies that bind cd123 and gamma-delta t cell receptors
JP2025532504A (ja) 抗ｉｌｔ４抗体及びその医薬的使用
WO2026008055A1 (zh) 抗kit抗体及其医药用途
CN117986371A (zh) 结合CD123和γ-δT细胞受体的抗体